Across the United States, several emerging policies are putting both medical innovation and patient access to lifesaving drugs at risk.

Although these measures are often promoted as efforts to reduce healthcare costs and assert greater national control, they could end up limiting access to new treatments and slowing scienitific progress. Patients have strong reasons to be concerned about the long-term consequences.

One major concern is a recent executive order by President Donald Trump that ties Medicaid’s drug prices to those of “most favored nations,” effectively capping U.S. prices at levels paid by countries with government-imposed price controls.

Read more at Newsmax© 2025 Newsmax. All rights reserved.